From charcot to lou gehrig: deciphering selective motor neuron death in als
暂无分享,去创建一个
[1] M. Swash,et al. Ubiquitin deposits in anterior horn cells in motor neurone disease , 1988, Neuroscience Letters.
[2] A. Levey,et al. Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis , 1995, Annals of neurology.
[3] L. Kurland,et al. Familial adult motor neuron disease: amyotrophic lateral sclerosis , 1986, Neurology.
[4] Lin Jin,et al. Aberrant RNA Processing in a Neurodegenerative Disease: the Cause for Absent EAAT2, a Glutamate Transporter, in Amyotrophic Lateral Sclerosis , 1998, Neuron.
[5] P. Leigh,et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis , 1996, The Lancet.
[6] V. Meininger,et al. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients , 2002, Journal of the Neurological Sciences.
[7] M. Baudry,et al. Synthetic superoxide dismutase/catalase mimetics reduce oxidative stress and prolong survival in a mouse amyotrophic lateral sclerosis model , 2001, Neuroscience Letters.
[8] C. van Broeckhoven,et al. Further evidence that neurofilament light chain gene mutations can cause Charcot‐Marie‐Tooth disease type 2E , 2001, Annals of neurology.
[9] A. Favier,et al. A double-blind, placebo-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis , 2001 .
[10] M. Gurney,et al. Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[11] H. Schmalbruch,et al. Protective effects of cardiotrophin-1 adenoviral gene transfer on neuromuscular degeneration in transgenic ALS mice. , 2001, Human molecular genetics.
[12] T. Crawford,et al. Subunit composition of neurofilaments specifies axonal diameter , 1996, The Journal of cell biology.
[13] J. Julien,et al. Extra Axonal Neurofilaments Do Not Exacerbate Disease Caused by Mutant Cu,Zn Superoxide Dismutase , 2000, Neurobiology of Disease.
[14] J. Haines,et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.
[15] O. Andreassen,et al. Effects of an Inhibitor of Poly(ADP-Ribose) Polymerase, Desmethylselegiline, Trientine, and Lipoic Acid in Transgenic ALS Mice , 2001, Experimental Neurology.
[16] P. Nunn,et al. Guam ALS-PDC: possible causes. , 1993, Science.
[17] V. Meininger,et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. , 1994, The New England journal of medicine.
[18] M. Swash,et al. Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis. Morphology, distribution, and specificity. , 1991, Brain : a journal of neurology.
[19] M. Harrison,et al. Calcium metabolism in osteoporosis. Acute and long-term responses to increased calcium intake. , 1961, Lancet.
[20] P. Ince,et al. CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[21] A Al-Chalabi,et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. , 1999, Human molecular genetics.
[22] Wendy Bruening,et al. Up‐Regulation of Protein Chaperones Preserves Viability of Cells Expressing Toxic Cu/Zn‐Superoxide Dismutase Mutants Associated with Amyotrophic Lateral Sclerosis , 1999, Journal of neurochemistry.
[23] Q. Zhu,et al. Protective effect of neurofilament heavy gene overexpression in motor neuron disease induced by mutant superoxide dismutase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[24] J. Coyle,et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis , 1990, Annals of neurology.
[25] Georg Grön,et al. The RNA of the glutamate transporter EAAT2 is variably spliced in amyotrophic lateral sclerosis and normal individuals , 1999, Journal of the Neurological Sciences.
[26] A. Ludolph,et al. LATHYRISM: EVIDENCE FOR ROLE OF THE NEUROEXCITATORY AMINOACID BOAA , 1986, The Lancet.
[27] S. Hadano,et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2 , 2001, Nature Genetics.
[28] D. Cleveland,et al. Slowing of axonal transport is a very early event in the toxicity of ALS–linked SOD1 mutants to motor neurons , 1999 .
[29] A. Nersissian,et al. Loss of in Vitro Metal Ion Binding Specificity in Mutant Copper-Zinc Superoxide Dismutases Associated with Familial Amyotrophic Lateral Sclerosis* , 2000, The Journal of Biological Chemistry.
[30] F. Uckun,et al. Genistein is neuroprotective in murine models of familial amyotrophic lateral sclerosis and stroke. , 1999, Biochemical and biophysical research communications.
[31] J. Coyle,et al. Excitatory amino acids in amyotrophic lateral sclerosis: An update , 1991, Annals of neurology.
[32] Robert G. Miller,et al. A clinical trial of verapamil in amyotrophic lateral sclerosis , 1996, Muscle & nerve.
[33] S. Sakoda,et al. Benefit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model mice , 1999, Neuroscience Letters.
[34] Till Acker,et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration , 2001, Nature Genetics.
[35] K. Csiszȧr,et al. Intrathecal cyclosporin prolongs survival of late-stage ALS mice , 2001, Brain Research.
[36] N. Ende,et al. Human umbilical cord blood effect on sod mice (amyotrophic lateral sclerosis). , 2000, Life sciences.
[37] D. Bredesen,et al. Altered Reactivity of Superoxide Dismutase in Familial Amyotrophic Lateral Sclerosis , 1996, Science.
[38] J. Haines,et al. Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. , 2000, JAMA.
[39] M. Gurney,et al. Protein Oxidative Damage in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis , 1998, Journal of neurochemistry.
[40] J. Julien,et al. Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: A mouse model of amyotrophic lateral sclerosis , 1993, Cell.
[41] E. Berkman,et al. Therapeutic plasmapheresis and plasma exchange. , 1986, Critical reviews in clinical laboratory sciences.
[42] J. Kong,et al. Massive Mitochondrial Degeneration in Motor Neurons Triggers the Onset of Amyotrophic Lateral Sclerosis in Mice Expressing a Mutant SOD1 , 1998, The Journal of Neuroscience.
[43] S. Minotti,et al. Mutant Cu/Zn-Superoxide Dismutase Proteins Have Altered Solubility and Interact with Heat Shock/Stress Proteins in Models of Amyotrophic Lateral Sclerosis* , 2001, The Journal of Biological Chemistry.
[44] D. Price,et al. Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[45] P. Leigh,et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis , 1998, Neurology.
[46] H. R. Tyler,et al. The use of isoprinosine in patients with amyotrophic lateral sclerosis , 1971, Neurology.
[47] M. Gurney,et al. Benefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosis , 1996, Annals of neurology.
[48] D. Figlewicz,et al. Nitrotyrosination contributes minimally to toxicity of mutant SOD1 associated with ALS , 2001, Neuroreport.
[49] M. Beal,et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury , 1996, Nature Genetics.
[50] D. Borchelt,et al. ALS-Linked SOD1 Mutant G85R Mediates Damage to Astrocytes and Promotes Rapidly Progressive Disease with SOD1-Containing Inclusions , 1997, Neuron.
[51] J. Haines,et al. Genetic mapping of a mouse modifier gene that can prevent ALS onset. , 2000, Genomics.
[52] O. Evgrafov,et al. A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. , 2000, American journal of human genetics.
[53] L. WilliamsonT,et al. 神経フィラメントの欠如は,家族性筋萎縮性側索硬化症関連スーパオキジドジスムターゼ1変異に対する運動ニューロンの選択的易損性を低下させ,疾患を遅らせる , 1998 .
[54] Jeffrey A. Cohen,et al. A double‐blind, placebo‐controlled trial of TRH in amyotrophic lateral sclerosis , 1986, Neurology.
[55] J. Julien,et al. Deregulation of Cdk5 in a Mouse Model of ALS Toxicity Alleviated by Perikaryal Neurofilament Inclusions , 2001, Neuron.
[56] D. Borchelt,et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria , 1995, Neuron.
[57] V. Meininger,et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. , 1994, Human molecular genetics.
[58] T. Munsat,et al. Intrathecal administration of natural human nterferon alpha in amyotrophic lateral sclerosis , 1986, Neurology.
[59] R. Sufit,et al. Intravenous thyrotropin-releasing hormone in patients with amyotrophic lateral sclerosis. Dose-response and randomized concurrent placebo-controlled pilot studies. , 1987, Neurologic clinics.
[60] P. Andersen,et al. Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase , 1995, Nature Genetics.
[61] P. Ince,et al. Oxidative damage to protein in sporadic motor neuron disease spinal cord , 1995, Annals of neurology.
[62] R. Fallat,et al. Trial of octacosanol in amyotrophic lateral sclerosis , 1986, Neurology.
[63] K. Johnson. An Update. , 1984, Journal of food protection.
[64] L. Cork,et al. Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease , 1993, Cell.
[65] L. Bruijn,et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. , 1998, Science.
[66] T. Munsat,et al. Amantadine and guanidine are ineffective in ALS , 1981, Neurology.
[67] M. Swash,et al. Histochemical and immunocytochemical study of ubiquitinated neuronal inclusions in amyotrophic lateral sclerosis , 1993, Neuropathology and applied neurobiology.
[68] A. Hirano,et al. Fine Structural Observations of Neurofilamentous Changes in Amyotrophic Lateral Sclerosis , 1984, Journal of neuropathology and experimental neurology.
[69] M. Gurney,et al. Relationship of oxygen radical‐induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS , 1998, Journal of neuroscience research.
[70] P. Andres,et al. Intrathecal thyrotropin‐releasing hormone does not alter the progressive course of ALS , 1992, Neurology.
[71] V. Appel,et al. A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. , 1988, Archives of neurology.
[72] M. Mohajeri,et al. Intramuscular grafts of myoblasts genetically modified to secrete glial cell line-derived neurotrophic factor prevent motoneuron loss and disease progression in a mouse model of familial amyotrophic lateral sclerosis. , 1999, Human gene therapy.
[73] J. Thompson,et al. Decreased Zinc Affinity of Amyotrophic Lateral Sclerosis‐Associated Superoxide Dismutase Mutants Leads to Enhanced Catalysis of Tyrosine Nitration by Peroxynitrite , 1997, Journal of neurochemistry.
[74] J S Beckman,et al. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. , 1999, Science.
[75] D L Price,et al. Copper chaperone for superoxide dismutase is essential to activate mammalian Cu/Zn superoxide dismutase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[76] M. Pericak-Vance,et al. Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers , 1998, Neurogenetics.
[77] M. Pericak-Vance,et al. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. , 1993, Science.
[78] L. Rowland,et al. Transfer factor is ineffective in amyotrophic lateral sclerosis , 1979, Annals of neurology.
[79] Olivier Curet,et al. Beneficial Effects of Lysine Acetylsalicylate, a Soluble Salt of Aspirin, on Motor Performance in a Transgenic Model of Amyotrophic Lateral Sclerosis , 1999, Experimental Neurology.
[80] P. Stieg,et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. , 2000, Science.
[81] D. Borchelt,et al. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[82] M. Carson,et al. ALS, SOD and peroxynitrite , 1993, Nature.
[83] O. Andreassen,et al. N‐acetyl‐L‐cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis , 2000, Neuroreport.
[84] T. Munsat,et al. A double‐blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis , 1984, Neurology.
[85] G. Rosoklija,et al. Recruitment of the Mitochondrial-Dependent Apoptotic Pathway in Amyotrophic Lateral Sclerosis , 2001, The Journal of Neuroscience.
[86] P. Sham,et al. Recessive amyotrophic lateral sclerosis families with the D90A SOD1 mutation share a common founder: evidence for a linked protective factor. , 1998, Human molecular genetics.
[87] L. Kurland,et al. Follow-up study on amyotrophic lateral sclerosis in Rochester, Minn., 1925 through 1984. , 1986, Neuroepidemiology.
[88] R. Casareno,et al. The Copper Chaperone for Superoxide Dismutase* , 1997, The Journal of Biological Chemistry.
[89] M. Gaweł,et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. , 1997, Neurology.
[90] Ole A. Andreassen,et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis , 1999, Nature Medicine.
[91] P. Andersen,et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. , 1996, Brain : a journal of neurology.
[92] P. Andersen. Genetics of sporadic ALS , 2001, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[93] J. Turnbull,et al. Beneficial effect of ginseng root in SOD-1 (G93A) transgenic mice , 2000, Journal of the Neurological Sciences.
[94] J. Holstege,et al. Human Cu/Zn Superoxide Dismutase (SOD1) Overexpression in Mice Causes Mitochondrial Vacuolization, Axonal Degeneration, and Premature Motoneuron Death and Accelerates Motoneuron Disease in Mice Expressing a Familial Amyotrophic Lateral Sclerosis Mutant SOD1 , 2000, Neurobiology of Disease.
[95] D. Figlewicz,et al. Aggregation of Mutant Cu/Zn Superoxide Dismutase Proteins in a Culture Model of ALS , 1997, Journal of neuropathology and experimental neurology.
[96] Robert H. Brown,et al. Superoxide Dismutase Activity, Oxidative Damage, and Mitochondrial Energy Metabolism in Familial and Sporadic Amyotrophic Lateral Sclerosis , 1993, Journal of neurochemistry.
[97] L. Bruijn,et al. Toxicity of ALS-linked SOD1 mutants. , 2000, Science.
[98] Shen,et al. Carboxyfullerenes as neuroprotective agents. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[99] Q. Zhu,et al. Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[100] Jm Charcot,et al. Deux cas d’atrophie musculaire progressive avec lesions de la substance grise et des faisceaux antero-lateraux de la moelle epiniere , 1869 .
[101] D. Cleveland,et al. Caspase-1 and -3 are sequentially activated in motor neuron death in Cu,Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[102] L. Honig,et al. Glutamate transporter EAAT2 splice variants occur not only in ALS, but also in AD and controls , 2000, Neurology.
[103] X. P. Liu,et al. A specific inhibitor of janus kinase-3 increases survival in a transgenic mouse model of amyotrophic lateral sclerosis. , 2000, Biochemical and biophysical research communications.
[104] M. Akbar,et al. Expression of glial glutamate transporters GLT-1 and GLAST is unchanged in the hippocampus in fully kindled rats , 1997, Neuroscience.
[105] P. Dyck,et al. Morphometric Comparison of the Vulnerability of Peripheral Motor and Sensory Neurons in Amyotrophic Lateral Sclerosis , 1981, Journal of neuropathology and experimental neurology.
[106] M. Reinholz,et al. Therapeutic Benefits of Putrescine-Modified Catalase in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis , 1999, Experimental Neurology.
[107] K. Roemer,et al. Motor neuron cell death in a mouse model of FALS is not mediated by the p53 cell survival regulator , 2000, Brain Research.
[108] O. Andreassen,et al. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation , 2001, Journal of neurochemistry.
[109] J. Kong,et al. Overexpression of neurofilament subunit NF-L and NF-H extends survival of a mouse model for amyotrophic lateral sclerosis , 2000, Neuroscience Letters.
[110] J. Morrison,et al. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[111] W. Snider,et al. Restricted Expression of G86R Cu/Zn Superoxide Dismutase in Astrocytes Results in Astrocytosis But Does Not Cause Motoneuron Degeneration , 2000, The Journal of Neuroscience.
[112] Junying Yuan,et al. Inhibition of ICE slows ALS in mice , 1997, Nature.
[113] M. Hallett,et al. Ganglioside therapy for amyotrophic lateral sclerosis , 1984, Neurology.
[114] R. Mason,et al. Reexamination of the mechanism of hydroxyl radical adducts formed from the reaction between familial amyotrophic lateral sclerosis-associated Cu,Zn superoxide dismutase mutants and H2O2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[115] M. Yahr,et al. PILOT TRIAL OF BRANCHED-CHAIN AMINOACIDS IN AMYOTROPHIC LATERAL SCLEROSIS , 1988, The Lancet.
[116] W. Robberecht,et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. , 1998, Neurology.
[117] T. Siddique,et al. Current status of SOD1 mutations in familial amyotrophic lateral sclerosis. , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[118] A. Pestronk,et al. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation , 1994, Annals of neurology.
[119] R. Orrell,et al. A novel SOD mutant and ALS , 1995, Nature.
[120] B. Crain,et al. Autosomal dominant juvenile amyotrophic lateral sclerosis. , 1999, Brain : a journal of neurology.
[121] M. Dubois‐Dauphin,et al. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. , 1997, Science.
[122] Robert H. Brown,et al. Increased 3‐nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis , 1997, Annals of neurology.
[123] H. Horvitz,et al. Superoxide Dismutase Concentration and Activity in Familial Amyotrophic Lateral Sclerosis , 1995, Journal of neurochemistry.
[124] M. Gurney,et al. Lack of involvement of neuronal nitric oxide synthase in the pathogenesis of a transgenic mouse model of familial amyotrophic lateral sclerosis , 1999, Neuroscience.
[125] M. Pericak-Vance,et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis , 2001, Nature Genetics.
[126] M. Gurney,et al. The Copper Chelator d‐Penicillamine Delays Onset of Disease and Extends Survival in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis , 1997, The European journal of neuroscience.
[127] M. Cudkowicz,et al. Administration of nitric oxide synthase inhibitors does not alter disease course of amyotrophic lateral sclerosis SOD1 mutant transgenic mice , 1999, Annals of neurology.
[128] M. Willard,et al. Modulations of neurofilament axonal transport during the development of rabbit retinal ganglion cells , 1983, Cell.
[129] Ole A. Andreassen,et al. Mice with a Partial Deficiency of Manganese Superoxide Dismutase Show Increased Vulnerability to the Mitochondrial Toxins Malonate, 3-Nitropropionic Acid, and MPTP , 2001, Experimental Neurology.
[130] A. Pramatarova,et al. Neuron-Specific Expression of Mutant Superoxide Dismutase 1 in Transgenic Mice Does Not Lead to Motor Impairment , 2001, The Journal of Neuroscience.
[131] M. Hediger,et al. Knockout of Glutamate Transporters Reveals a Major Role for Astroglial Transport in Excitotoxicity and Clearance of Glutamate , 1996, Neuron.
[132] Masahiko Watanabe,et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. , 1997, Science.
[133] D. Cleveland,et al. A mutant neurofilament subunit causes massive, selective motor neuron death: Implications for the pathogenesis of human motor neuron disease , 1994, Neuron.
[134] L. Kurland,et al. Fine Structural Study of Neurofibrillary Changes in a Family with Amyotrophic Lateral Sclerosis , 1984, Journal of neuropathology and experimental neurology.
[135] M. Gurney,et al. Increased 3‐nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation , 1997, Annals of neurology.
[136] M. Dubois‐Dauphin,et al. Delaying Caspase Activation by Bcl-2: A Clue to Disease Retardation in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis , 2000, The Journal of Neuroscience.
[137] N. Laing,et al. Toxic mutants in Charcot's sclerosis , 1995, Nature.
[138] M. Gurney,et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. , 1994, Science.
[139] P. Leigh,et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. , 1996, Lancet.
[140] V. Culotta,et al. Chaperone-facilitated copper binding is a property common to several classes of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[141] Robert H. Brown,et al. Evidence of Increased Oxidative Damage in Both Sporadic and Familial Amyotrophic Lateral Sclerosis , 1997, Journal of neurochemistry.
[142] Robert G. Miller,et al. Controlled trial of nimodipine in amyotrophic lateral sclerosis , 1996, Neuromuscular Disorders.
[143] J. Slade,et al. Novel insertion in the KSP region of the neurofilament heavy gene in amyotrophic lateral sclerosis (ALS) , 1998, Neuroreport.
[144] W. Bradley. A controlled trial of recombinant methionyl human BDNF in ALS , 1999, Neurology.
[145] D. Borchelt,et al. Superoxide Dismutase 1 Subunits with Mutations Linked to Familial Amyotrophic Lateral Sclerosis Do Not Affect Wild-type Subunit Function (*) , 1995, The Journal of Biological Chemistry.
[146] S. Carpenter. Proximal axonal enlargement in motor neuron disease , 1968, Neurology.
[147] B. Crain,et al. Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. , 1998, American journal of human genetics.
[148] M. Gurney,et al. Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. , 1994, The American journal of pathology.
[149] A. Favier,et al. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. , 2001, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[150] C. Heizmann,et al. Parvalbumin and calbindin D‐28k in the human motor system and in motor neuron disease , 1993, Neuropathology and applied neurobiology.
[151] W. Olson,et al. Therapeutic trial of tilorone in ALS , 1978, Neurology.